RhumbLine Advisers’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,366
| Closed | -$52.8K | – | 4244 |
|
|
2024
Q2 | $52.8K | Sell |
2,366
-3,924
| -62% | -$121K | ﹤0.01% | 3667 |
|
|
2024
Q1 | $370K | Buy |
6,290
+107
| +2% | +$4.61K | ﹤0.01% | 2847 |
|
|
2023
Q4 | $137K | Hold |
6,183
| – | – | ﹤0.01% | 3346 |
|
|
2023
Q3 | $133K | Sell |
6,183
-353
| -5% | -$13.9K | ﹤0.01% | 3361 |
|
|
2023
Q2 | $441K | Buy |
6,536
+1,216
| +23% | +$503K | ﹤0.01% | 2774 |
|
|
2023
Q1 | $2.48M | Buy |
5,320
+207
| +4% | +$110K | ﹤0.01% | 1697 |
|
|
2022
Q4 | $2.05M | Buy |
5,113
+110
| +2% | +$42.1K | ﹤0.01% | 1774 |
|
|
2022
Q3 | $1.63M | Buy |
5,003
+494
| +11% | +$159K | ﹤0.01% | 1869 |
|
|
2022
Q2 | $1.19M | Buy |
4,509
+520
| +13% | +$133K | ﹤0.01% | 2055 |
|
|
2022
Q1 | $1.2M | Sell |
3,989
-177
| -4% | -$61.7K | ﹤0.01% | 2062 |
|
|
2021
Q4 | $1.47M | Buy |
4,166
+16
| +0.4% | +$4.98K | ﹤0.01% | 2037 |
|
|
2021
Q3 | $1.06M | Sell |
4,150
-111
| -3% | -$39.3K | ﹤0.01% | 2205 |
|
|
2021
Q2 | $2.84M | Buy |
4,261
+215
| +5% | +$124K | ﹤0.01% | 1770 |
|
|
2021
Q1 | $3.51M | Sell |
4,046
-443
| -10% | -$472K | ﹤0.01% | 1604 |
|
|
2020
Q4 | $4.16M | Sell |
4,489
-110
| -2% | -$116K | 0.01% | 1462 |
|
|
2020
Q3 | $4.73M | Sell |
4,599
-1,157
| -20% | -$1.24M | 0.01% | 1205 |
|
|
2020
Q2 | $5.83M | Buy |
5,756
+726
| +14% | +$674K | 0.01% | 1110 |
|
|
2020
Q1 | $4.37M | Sell |
5,030
-22
| -0.4% | -$21.9K | 0.01% | 1101 |
|
|
2019
Q4 | $5.42M | Buy |
5,052
+214
| +4% | +$218K | 0.01% | 1208 |
|
|
2019
Q3 | $4.47M | Sell |
4,838
-92
| -2% | -$101K | 0.01% | 1247 |
|
|
2019
Q2 | $5.57M | Buy |
4,930
+507
| +11% | +$555K | 0.01% | 1131 |
|
|
2019
Q1 | $6.01M | Sell |
4,423
-45
| -1% | -$61K | 0.01% | 1072 |
|
|
2018
Q4 | $5.17M | Buy |
4,468
+1,592
| +55% | +$1.79M | 0.01% | 1084 |
|
|
2018
Q3 | $4.37M | Sell |
2,876
-302
| -10% | -$465K | 0.01% | 1200 |
|
|
2018
Q2 | $4.97M | Buy |
3,178
+373
| +13% | +$486K | 0.01% | 1101 |
|
|
2018
Q1 | $3.24M | Sell |
2,805
-15
| -0.5% | -$19.8K | 0.01% | 1314 |
|
|
2017
Q4 | $3.34M | Sell |
2,820
-441
| -14% | -$553K | 0.01% | 1317 |
|
|
2017
Q3 | $4.39M | Buy |
3,261
+534
| +20% | +$563K | 0.01% | 1109 |
|
|
2017
Q2 | $2.2M | Buy |
2,727
+280
| +11% | +$195K | 0.01% | 1517 |
|
|
2017
Q1 | $1.51M | Buy |
2,447
+175
| +8% | +$107K | ﹤0.01% | 1710 |
|
|
2016
Q4 | $1.22M | Buy |
2,272
+188
| +9% | +$93.9K | ﹤0.01% | 1750 |
|
|
2016
Q3 | $1.08M | Buy |
2,084
+47
| +2% | +$22.1K | ﹤0.01% | 1768 |
|
|
2016
Q2 | $836K | Buy |
2,037
+193
| +10% | +$88.4K | ﹤0.01% | 1898 |
|
|
2016
Q1 | $981K | Buy |
1,844
+6
| +0.3% | +$2.99K | ﹤0.01% | 1814 |
|
|
2015
Q4 | $1.4M | Buy |
1,838
+147
| +9% | +$97.6K | ﹤0.01% | 1588 |
|
|
2015
Q3 | $926K | Buy |
1,691
+70
| +4% | +$42.4K | ﹤0.01% | 1811 |
|
|
2015
Q2 | $953K | Buy |
1,621
+1,366
| +536% | +$794K | ﹤0.01% | 1896 |
|
|
2015
Q1 | $200K | Buy |
+255
| New | +$198K | ﹤0.01% | 2829 |
|
Other funds holding KYNB
AC
6CM
GC
RhumbLine Advisers's KYNB Position: Q3 2024 in Review
RhumbLine Advisers sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 2,366 shares — an estimated $52.8K sold.
RhumbLine Advisers first reported a position in KYNB in Q1 2015 and held it in 38 quarters. The position peaked at $6.01M in Q1 2019. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.
- RhumbLine Advisers reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
- RhumbLine Advisers sold 2,366 Kyntra Bio shares in Q3 2024, an estimated $52.8K.
- RhumbLine Advisers first reported a position in Kyntra Bio in Q1 2015 and held it in 38 quarters.
- RhumbLine Advisers's Kyntra Bio position peaked at $6.01M in Q1 2019.
- 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.
Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.